A print magazine focussing on start-ups in the life sciences! Like a catalyst, it aims to promote young companies in the life sciences with the right impulses.
ADVERTISEMENT
Evotec SE has reached a predefined milestone worth €20m in the CRO’s partnership with Bristol Myers Squibb (BMS).
Glycan target specialist Tacalyx GmbH expands its seed financing to €14m to advance its anti-TACA cancer therapies.
Researchers at University Hospital Hamburg-Eppendorf have laid the foundation to screen for molecules that shift Th17 cells from proinflammatory or immune-dampening mode.
GSK takes over Elsie Biotechnologies in US$50m deal to boost its oligonucleotide-based drug platform and pipeline.
ITM Isotope Technologies Munich SE has raised €188m ito boost radiopharma pipeline, contract manufacturing cpacity, and launch ITM-11.
Viennese biotech QUANTRO Therapeutics identifies small molecule targeting an onkogenic transcription factor in Boehringer Ingelheim collab.
At the end of May, Dr Uwe Meya took over as Chief Medical Officer at Oxford-based SynaptixBio.
DefiniGEN Ltd., and Atelerix Ltd. have successfully shipped in vitro liver models from the UK to the US without freezing them thus preventing cell damage and loss-of function.
440 participants discussed the defossilisation of the chemical and materials industry through biomass, CO2 and recycling. The audience voted for the “Renewable Material of the Year 2024”: Acetic acid from CO2 by Danish start-up Again wins 1st price.